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Abstract
Background: 131I and 211At are used in nuclear medicine and accumulate in the thyroid gland and may impact normal
thyroid function. The aim of this study was to determine transcriptional profile variations, assess the impact on cellular
activity, and identify genes with biomarker properties in thyroid tissue after 131I and 211At administration in mice.
Methods: To further investigate thyroid tissue transcriptional responses to 131I and 211At administration, we generated
a new transcriptional dataset that includes re-evaluated raw intensity values from our previous 131I and 211At studies.
Differential transcriptional profiles were identified by comparing treated and mock-treated samples using Nexus
Expression 3.0 software. Further data analysis was performed using R/Bioconductor and IPA.
Results: A total of 1144 genes were regulated. Hierarchical clustering subdivided the groups into two clusters containing
the lowest and highest absorbed dose levels, respectively, and revealed similar transcriptional regulation patterns for
many kallikrein-related genes. Twenty-seven of the 1144 genes were recurrently regulated after 131I and 211At exposure
and divided into six clusters. Several signalling pathways were affected, including calcium, integrin-linked kinase, and
thyroid cancer signalling, and the peroxisomal proliferator-activated receptor network.
Conclusions: Substantial changes in transcriptional regulation were shown in 131I and 211At-treated samples, and 27
genes were identified as potential biomarkers for 131I and 211At exposure. Clustering revealed distinct differences between
transcriptional profiles of both similar and different exposures, demonstrating the necessity for better understanding of
radiation-induced effects on cellular activity. Additionally, ionizing radiation-induced changes in kallikrein gene expression
and identified canonical pathways should be further assessed.
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Background
Medical applications for radionuclides are rapidly devel-
oping. The β particle-emitting 131I is frequently included
in therapy regimens of various thyroid disorders due to
selective uptake of the isotope in thyroid tissue and is
also administered bound to tumour-seeking agents for
therapeutic and diagnostic purposes [1–4]. The α particle-
emitting 211At is a suitable therapeutic radionuclide due
to, e.g., a nearly optimal therapeutic linear energy transfer
value of emitted α particles of 98.8 keV/μm [5]. 211At-la-
belled tumour-seeking pharmaceuticals have been utilized
both in humans and in animals [6–8]. Similar to unbound
131I, selective uptake of unbound 211At also occurs in thy-
roid tissue [9–11], and administration of free 131I and
211At or 131I- and 211At-labelled radiopharmaceuticals
have been shown to result in thyroid irradiation [6, 12].
Additionally, nuclear accidents often involve an atmos-
pheric release of 131I, as was the case in connection with
the Chernobyl accident, which resulted in an increased in-
cidence of thyroid cancer in children [13, 14].
Despite the risk of exposing thyroid tissue to 131I and
211At, the understanding of radiation-induced effects is far
from complete and molecular biomarkers of absorbed
dose or radiation-induced effects on thyroid tissue are yet
to be identified. Biomarkers are useful to indicate achieved
therapeutic effects or estimate risk exposure and evaluate
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the quality and severity of side effects. RNA microarray
analysis is a semi-quantitative method to identify changes
in genome-wide transcriptional patterns between two or
more samples. The result is a transcriptional profile, i.e. a
snapshot of the radiation-induced cellular activity at the
mRNA level. This can be used to determine the impact of
radiation on biological functions and canonical pathways,
to predict upstream regulation of target molecules, and
for biomarker discovery without the risk of bias in focus-
ing on a specific set of signalling pathways only.
Few investigations on global gene expression effects of α
and β particle irradiation have been performed in normal
(thyroid) tissue in vivo. There are, however, a few in vitro
studies on global gene expression in fibroblasts and cancer
cells after α particle exposure [15, 16]. Additionally, effects
on gene expression for a set of pre-defined genes after α
particle irradiation have been measured both in cancer
cells in vitro and in vivo in xenografted tumours [17–19].
Previously, we have published results showing substantial
differences between transcriptional profiles in thyroid
tissue in vivo after different 131I or 211At exposures, varying
absorbed dose, dose rate and time after administration
[20–22]. We then identified potential biomarkers for each
type of exposure separately and concluded that biological
response to radiation is complex and that it is difficult to
predict or extrapolate radiation-induced effects for other
exposure parameters.
The aim of this work was to re-evaluate the previously
obtained transcriptional response in thyroid after admin-
istration of 131I− and free 211At in mice from different
exposure conditions to gain a better understanding of
variations in transcriptional regulation on absorbed dose,
dose rate, time after administration and radiation quality.
Methods
Study design
In this study, we further investigate the thyroid transcrip-
tional response to 131I and 211At exposure by using nor-
malized intensity values from three different experiments
where separate analyses of each experiment have been
published elsewhere [20–22]. All normalized intensity
values (normalization was performed according to ex-
periment) from these three experiments were imported
together into Nexus Expression 3.0 (BioDiscovery; El
Segundo, CA) for filtering, linear modelling and deter-
mination of differentially expressed genes.
No new tissue sampling and analysis was thus performed
in this study, but a reanalysis of all these data together in a
new analysis by Nexus Expression. Data presented in the
present work are therefore novel and have not been previ-
ously published.
A brief summary of the methods used in the three ori-
ginal studies is as follows: a total of 44 female Balb/c nude
mice (CAnN.Cg-Foxn1nu/Crl, Charles River Laboratories
International, Inc., Salzfeld, Germany) (n = 2–3 per group)
were i.v. injected with various amounts of 131I or 211At in
the tail vein and killed at 1, 6, 24 or 168 h after adminis-
tration, or mock-treated (Table 1). Thyroid, kidney, liver,
lung and spleen tissue samples were collected and imme-
diately snap-frozen in liquid nitrogen and stored at −80 °C
until RNA extraction. The present study contains data on
transcriptional changes in thyroid glands. The transcrip-
tional response in the kidneys, livers, lungs and spleens
has been published elsewhere [23–25].
The methods for determination of absorbed doses
have been reported previously with separate analysis of
each experiment [20–22]. In short, the mean absorbed
dose was calculated according to conventional Medical
Internal Radiation Dose (MIRD) formalism. We used
previously published data on relative activity concentra-
tion of 131I and 211At in thyroid in mice [26], an
absorbed fraction of 0.742 and 1 for radiation emitted
from 131I and 211At, respectively [27], and a standard
mouse thyroid mass of 3 mg.
Gene expression analysis
Genome-wide transcriptional analysis using RNA
microarray of thyroid tissue has been described else-
where [20, 21]. Briefly, RNA samples were analysed using
MouseRef-8 Whole-Genome Expression Beadchips (Illu-
mina; San Diego, CA, USA). Nexus Expression 3.0 (BioDis-
covery; El Segundo, CA) was used to identify statistically
significant differentially expressed transcripts (≥1.5-fold
change) with a Benjamini-Hochberg adjusted p value
cut-off of 0.01 between irradiated and control tissues. RNA
microarray data from irradiated samples were compared
Table 1 Number of regulated genes in thyroid tissue in mice











211At 1 1.7 0.023 3 210 92 118
100 1.4 3 630 345 285
6 1.7 0.32 3 170 51 119
7.5 1.4 3 290 116 174
24 0.064 0.05 3 360 254 106
0.64 0.5 3 157 95 62
1.7 1.4 3 359 149 210
14 11 3 464 339 125
42 32 3 357 251 106
168 1.7 1.8 3 136 49 87
131I 24 13 0.85 2 227 101 126
130 8.5 2 266 138 128
260 17 2 55 37 18
Absorbed dose was calculated using MIRD formalism
Abbreviations: Δt exposure time, A injected activity, D absorbed dose
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with RNA microarray data from control animals from each
separate experiment to ensure that differential expression
of genes reflects radiation-induced changes and not varia-
tions between different control groups. There was one dif-
ference in study design between the present and previous
studies. In the present work, data from tissue samples from
animals administered 0.064 and 0.64 kBq 211At and killed
24 h after administration were compared with data from
tissue samples from control animals killed the same day.
However, in the previous paper with analysis of the tran-
scriptional response at 24 h after 211At administration, ani-
mals administered 0.064 and 0.64 kBq were compared with
controls killed earlier (killed simultaneously as animals
injected with 1.7, 14 and 42 kBq, also at 24 h after ad-
ministration but on another day) [20]. In the present
paper, the term “regulated transcripts/genes” is used
synonymous to “statistically significant differentially
expressed transcripts/genes”.
Hierarchical clustering of regulated transcripts according
to their transcriptional regulation profile was performed
using the hclust function (stats package, version 3.1.1) with
the complete linkage algorithm and Lance-Williams dis-
similarity update formula in the R statistical computing en-
vironment (version 0.97.551, http://www.r-project.org) [28].
Heat maps were produced using the heatmap.2 function
(gplots package, version 2.14.2).
Upstream regulation, diseases and functions and canon-
ical pathway analyses were generated using the Ingenuity
Pathway Analysis tool (IPA, Ingenuity® Systems, www.in-
genuity.com; Redwood City, CA) with Fisher’s exact test
(p value <0.05).
Gene expression data discussed in this publication have
been deposited at the NCBI’s Gene Expression Omnibus




In the present study, 1144 genes (1164 transcripts) were
regulated. The number of regulated genes in each group
varied between 55 (17 Gy, 24 h, 131I) and 630 (1.4 Gy,
1 h 211At) (Table 1). Hierarchical clustering subdivided
the exposure groups into two larger clusters: one smaller
branch containing groups with higher absorbed dose
levels (1.4–32 Gy from 211At and 8.5 Gy from 131I at
24 h) and a larger branch with the remaining groups
(Fig. 1).
At both 1 h and 6 h after 211At administration, a
higher absorbed dose/dose rate resulted in a higher
number of regulated genes (Table 1). In contrast, at 24 h
after 211At administration, the number of regulated
genes varied non-monotonously with absorbed dose. A
slight increase in the number of genes regulated after
131I exposure was seen between 0.85 and 8.5 Gy and a
decrease between 8.5 and 17 Gy. Transcriptional profiles
at 1, 6 and 168 h clustered together, with the exception
of 1.4 Gy at 1 h (Fig. 1). At 24 h, the transcriptional pro-
files for 0.05 and 0.5 Gy clustered together while the
profiles for 1.4, 11 and 32 Gy clustered together with
highest similarity between 11 and 32 Gy. Furthermore,
upregulation of 110 genes was shared between 0.05 and
1.4 Gy at 24 and 1 h after 211At administration, respect-
ively. For 131I exposure, the transcriptional profiles for
0.85 and 17 Gy clustered together, whereas the response
after 8.5 Gy was more similar to that after 1.4, 11 and
32 Gy at 24 h following 211At administration. In the
groups exposed to 1.4 Gy, the number of regulated
genes decreased from 630 to 290 between 1 and 6 h, but
increased to 359 at 24 h (Table 1). Additionally, the tran-
scriptional profiles of these groups showed little similar-
ity in the cluster analysis (Fig. 1). Lastly, an equal
amount of injected activity (1.7 kBq, 211At) resulted in
210, 170, 359 and 136 regulated genes at 0.023, 0.32, 1.4
and 1.8 Gy after 1, 6, 24 and 168 h, respectively (Table 1).
The transcriptional profiles of these groups were similar
and clustered together with the exception of 1.4 Gy at
24 h which was clearly different (Fig. 1).
Kallikrein 1 and kallikrein 1-related peptidases
Hierarchical clustering of all regulated transcripts revealed
similar transcriptional regulation profiles for 13 kallikrein
genes belonging to the peptidase S1 family (Klk1, Klk1b1,
Klk1b4, Klk1b5, Klk1b8, Klk1b9, Klk1b11, Klk1b16,
Klk1b21, Klk1b22, Klk1b24, Klk1b26 and Klk1b27 (A in
Figs. 1 and 2). All 13 genes were upregulated at 11 and
32 Gy 24 h after 211At administration. For an absorbed
dose of 1.4 Gy after 211At exposure, 9/13 kallikrein genes
were upregulated at 24 h but downregulated at 1 h (three
additional genes were downregulated at 1 h), while at 6 h,
1 and 4 genes were down- and upregulated, respectively.
Furthermore, 4/13 genes were upregulated at 1.8 Gy 168 h
after injection of 211At. At 24 h after 131I administration,
4/13 genes were upregulated after 17 Gy, but not regu-
lated at the lower absorbed dose levels.
Recurrently regulated genes after 131I and 211At exposure
Twenty-seven of the 1144 regulated genes were regu-
lated in ≥9 of the 13 groups (Fig. 3). Hierarchical cluster-
ing divided the 27 genes into six groups: 1) Atp2a1,
Ckm, Eno3, Pvalb, Tnnc2, Tnni2, Tnnt3; 2) Coq10b, Ctgf,
Dbp, Per1; 3) Mfsd2; 4) Ltf; 5) Ccl8, Ly6g6d, S100a8,
S100a9 and 6) Aoc3, Ccl9, Clec2d, Cpa3, Dpt, Fstl1,
Lum, Mup2, Ogn, Scara3. In cluster 1, genes were down-
regulated at 1 h following 211At administration. This
changed at 6 h where 0.32 and 1.4 Gy showed down-
and upregulation, respectively. At 24 h, the regulated genes
were upregulated and, notably, the fold change increased
with absorbed dose. At 24 h after 131I administration, all of
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these genes were upregulated with high fold changes
(21–180) after 8.5 Gy, while two genes were upregu-
lated to low extent after 17 Gy. Genes in cluster 2
were upregulated after 211At administration while 131I
administration resulted in both up- and downregula-
tion. The Mfsd2 gene, the only gene in cluster 3, was
up- and downregulated after 211At and 131I adminis-
tration, respectively. The Ltf gene, sole gene in cluster
Fig. 1 Results from hierarchical clustering analyses of genes and exposure groups after 131I and 211At exposure. Genes were hierarchically clustered
according to log2-ratio values using gplots package in R/Bioconductor. The columns represent genes and rows represent exposure type. Cluster
containing kallikrein genes is denoted A
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Fig. 2 Regulation of 13 kallikrein genes belonging to the peptidase S1 family after 131I and 211At exposure. Values indicate fold change of differential
gene expression. Green and red colours indicate up- and downregulation of genes, respectively. Higher saturation of colours indicates higher fold change
Fig. 3 Regulation of 27 recurrently regulated genes after 131I and 211At exposure. Values indicate fold change of differential gene expression.
Green and red colours indicate up- and downregulation of genes, respectively. Higher saturation of colours indicates higher fold change. The
relationships between genes and thyroid function, ionizing radiation, and thyroid cancer and biological function of genes have been assessed
using literature reports
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4 with almost opposite regulation to Mfsd2, was down-
regulated after 211At administration with the exception
of a 22-fold upregulation after 0.5 Gy at 24 h, and up-
regulated after 131I administration. Cluster 5 was simi-
lar to cluster 4, and 211At administration resulted in
downregulation with few exceptions of upregulation at
24 h and 131I administration generally resulted in up-
regulation. Genes in cluster 6 were generally downregu-
lated with the exception of upregulation at, e.g., 1.4–32
and 17 Gy 24 h after 211At and 131I administration,
respectively.
Canonical pathway analysis: calcium, integrin-linked kinase
and thyroid cancer signalling
In the present study, calcium, integrin-linked kinase and
thyroid cancer signalling were the top three canonical
pathways generated using the IPA comparison analysis
tool (Table 2). An impact on calcium signalling was sta-
tistically significant in all groups except at the two low-
est and the highest absorbed dose levels 24 h after 211At
and 131I administrations, respectively. Integrin-linked
kinase signalling was statistically significant in all groups
except at low absorbed dose levels at 1 and 24 h, and at
the lowest and highest absorbed dose levels 24 h after
211At and 131I administration, respectively. Genes associ-
ated with calcium and integrin-linked kinase signalling
were generally downregulated early and at low absorbed
doses and upregulated at later time points and at higher
absorbed doses. Thyroid cancer signalling was statisti-
cally significant in all groups except at 0.023 and
0.05 Gy, 1 and 24 h following 211At administration, re-
spectively, and at 0.85 and 8.5 Gy 24 h after 131I admin-
istration (Table 2). Additionally, the number of genes
involved in the different canonical pathways at each
time point generally increased with absorbed dose (with
exceptions between 11 and 32 Gy).
Diseases and function analysis: thyroid cancer and
disturbed thyroid function
A diseases and function analysis related to thyroid was gen-
erated with IPA (Table 3). At 6 (1.4 Gy) and 24 h (11 and
32 Gy) after 211At administration, a relation between the
transcriptional response and various thyroid cancer types
was identified. Such a relation was also identified 24 h after
131I administration; however, at a lower absorbed dose level
(0.85 and 8.5 Gy). Additionally, the transcriptional response
was linked to altered T3 and T4 levels and to thyroid gland
development at 0.32 and 32 Gy, 6 and 24 h after 211At ad-
ministration, respectively.
Upstream regulation of molecules related to peroxisomal
proliferator-activated receptors
The upstream regulation analysis generated by IPA pre-
dicted upstream regulation of various molecules related
to peroxisomal proliferator-activated receptors (PPARs)
(Table 4). These included PPARA, PPARD, PPARG,
PPARGC1A and several PPAR-targeting drugs and/or
PPAR ligands such as GW501516, mono-(2-ethylhex-
yl)phthalate, pirinixic acid, Rosiglitazone and Troglitazone.
IPA predicted that these upstream regulators were generally
activated at 1 h, for absorbed dose ≤1.4 Gy at 24 h, and for
1.8 Gy at 168 h.
Discussion
In the present study, the values used to calculate absorbed
dose were based on previously published 131I and 211At bio-
distribution data, where mice were simultaneously injected
with both 131I and 211At, which allows for direct compari-
son of the absorbed dose per injected activity between 131I
and 211At in the same animal [26]. In the present study,
radioactivity measurements of individual thyroid samples
would have enhanced the certainty in absorbed dose calcu-
lations but was not possible since all excised thyroid tissue
was needed to ensure sufficient amount of RNA for micro-
array analysis. There are several important differences in
the characteristics of 211At and 131I exposure: i) the differ-
ence in mean range of the α and β particles emitted (65
and 400 μm), ii) the much higher mean energy released per
decay from 211At compared with 131I (7000 and 190 keV),
iii) the difference in LET of particles emitted from 131I and
211At (0.25 and 98.8 keV/μm, respectively) and iv) much
shorter half-life for 211At than 131I (7.2 h and 8.0 day, re-
spectively). Taken together, 211At irradiates more heteroge-
neously and with higher dose rates at similar absorbed dose
levels compared with 131I (and the dose rate will decline
faster for 211At compared to 131I). The effects of radiation
quality on global gene expression should be further studied,
and to our knowledge, the present study is the first to in-
vestigate such differences between 131I and 211At.
RNA microarray analysis was used to evaluate the im-
pact of 131I and 211At exposure on global transcriptional
regulation in normal mouse thyroid tissue. Regulated
genes were associated with biological functions using
previously published literature reports and various data-
bases, in addition to upstream and downstream regula-
tion analysis and canonical pathway analysis generated
by Ingenuity Pathway Analysis (IPA) software. In total,
1144 genes were differentially regulated showing a large
variation in number of genes per group. In general, hier-
archical clustering divided groups that received high
absorbed doses into one branch and groups receiving
low absorbed doses into another. Thus, we hypothesize
that the transcriptional profiles presented here may re-
flect intrinsic biological properties predictive of 131I and
211At absorbed dose levels at various time points.
At both 1 and 6 h, the number of regulated genes in-
creased with absorbed dose. This was not the case for
131I or 211At exposure at 24 h, where a broader range of
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Table 2 Top three Ingenuity canonical pathways enriched by genes regulated after 131I or 211At exposure
Canonical pathway Nuclide Δt (h) D (Gy) p value Involved moleculesa
Calcium signalling 211At 1 0.023 0.035 DOWN: MYL1, TNNC2, TNNI2, TNNT3, TPM2
1.4 0.001 DOWN: ACTA1, ATP2A1, ATP2A3, Calm1 (includes others), MYH1, MYH2, MYH4, MYL1, TNNC2, TNNI2, TNNT3, TPM2 UP: LETM1, PRKACA
6 0.32 <0.0005 DOWN: ACTA1, ATP2A1, MYH1, MYL1, TNNC2, TNNI2, TNNT3, TPM2
1.4 <0.0005 DOWN: Calm1 (includes others) UP: ACTA, ATP2A1, ATP2A3, MYH, MYH2, MYH4, RYR1, TNNC2, TNNI2, TNNT3, TPM2
24 0.05 0.180 UP: ATP2A1, LETM1, MYH2, RYR1, TNNT3
0.5 0.390 UP: ATP2A1, MYH2
1.4 0.009 DOWN: ATP2A3 UP: ACTA1, ATP2A1, MYH4, TNNC2, TNNI2, TNNT3, TPM2
11 <0.0005 DOWN: Camk2b, LETM1 UP: ACTA1, ATP2A1, ATP2A3, Calm1 (includes others), CREB3L4, MYH1, MYH2, MYH4, MYL1, RYR1, TNNC2, TNNI2,
TNNT3, TP63, TPM2
32 <0.0005 DOWN: Camk2b, LETM1 UP: ACTA1, ATP2A1, ATP2A3, CREB3L4, MYH1, MYH2, MYH4, MYL1, RYR1, TNNC2, TNNI2, TNNT3, TPM2
168 1.8 0.027 DOWN: TNNC2, TNNI2, TNNT3 UP: MYL1
131I 24 0.85 – –
8.5 <0.0005 DOWN: MEF2C UP: ACTA1, ATP2A1, MYH1, MYH4, MYL1, RYR1, TNNC2, TNNI2, TNNT3, TPM2
17 0.071 UP: ACTA1, ATP2A1
Integrin-linked
kinase signalling
211At 1 0.023 0.291 DOWN: MYL1 UP: DSP, IRS2
1.4 <0.0005 DOWN: ACTA1, ACTB, Actn3, CCND1, ITGB6, KRT18, MYH1, MYH2, MYH4, MYL1, VIM UP: IRS2, LIMS2, SH2B2, VIM, ITGB6 UP/DOWN: PPP2R5A
6 0.32 0.004 DOWN: ACTA1, MYH1, MYL1 UP: DSP, IRS2, RHOU
1.4 0.001 DOWN: PPAP2B UP: ACTA1, ACTN2, Actn3, DSP, MYH1, MYH2, MYH4, RHOU
24 0.05 0.203 UP: ACTN2, LIMS2, MYH2, RHOT2 UP/DOWN: PPP2R5A
0.5 0.413 UP: ACTN2, MYH2
1.4 0.001 DOWN: ACTB, CCND1, CDH1, CTNNB1, ITGB4, KRT18 UP: ACTA1, FOS, IRS2, MYH4
11 <0.0005 DOWN: Irs3, VIM UP: ACTA1, Actn3, CDH1, CREB3L4, DSP, IRS2, ITGB4, ITGB6, MYH1, MYH2, MYH4, MYL1, KRT18
32 <0.0005 UP: ACTA1, ACTN2, Actn3, CDH1, CREB3L4, DSP, IRS2, ITGB4, ITGB6, KRT18, MYH1, MYH2, MYH4, MYL1
168 1.8 – –
131I 24 0.85 0.169 DOWN: ACTB, IRS2, PPAP2B UP: FOS
8.5 0.001 DOWN: IRS2 UP: ACTA1, ACTN2, Actn3, CCND1, FOS, MYH1, MYH4, MYL1
17 0.076 UP: ACTA1, CCND1
Thyroid cancer
signalling
211At 1 0.023 0.291 DOWN: MYL1 UP: DSP, IRS2
1.4 0.029 DOWN: CCND1, KLK3, NGF UP: PPARG
6 0.32 0.040 DOWN: NGF DOWN/UP: KLK3
1.4 0.019 UP: NGF, KLK3, RET
24 0.05 0.490 DOWN/UP: KLK3












Table 2 Top three Ingenuity canonical pathways enriched by genes regulated after 131I or 211At exposure (Continued)
1.4 0.004 DOWN: CCND1, CDH1, CTNNB1 UP: KLK3
11 <0.0005 DOWN: NTRK2, NTRK3, PPARG UP: CDH1, KLK3, NGF, RET
32 <0.0005 DOWN: NTRK2, NTRK3 UP: CDH1, KLK3, NGF, RET
168 1.8 0.026 UP: KLK3, NGF
131I 24 0.85 0.370 UP: PPARG
8.5 0.100 UP: CCND1, PPARG,
17 0.004 UP: CCND1, KLK3
DOWN and UP indicate down- and upregulation, respectively. Italics indicates no statistically significant effect on the specific canonical pathway
Abbreviations: Δt exposure time, D absorbed dose












Table 3 Results from IPA analysis of diseases and functions related to thyroid after 131I and 211At exposure
Nuclide Δt (h) D (Gy) Disease or function p value Involved moleculesa
211At 1 0.023
1.4
6 0.32 Dystransthyretinemic euthyroidal
hyperthyroxinemia
7.92E−03 UP: TTR
Quantity of L-triiodothyronine 2.65E−03 DOWN: LEP UP: TTR, UCP1
1.4 Differentiated thyroid cancer 4.63E−04 DOWN: IDH1, MMP2, PDGFRA, RAP1GAP, TEK, TGFBR2 UP: CDKN1A, RET,
Medullary thyroid cancer 1.01E−03 DOWN: AMY1A (includes others), PDGFRA, TEK UP: RET,





11 Metastasis of thyroid gland tumour 1.21E−03 DOWN: VIM UP: RET
Thyroid cancer 1.18E−03 DOWN: AMY1A (includes others), NTRK2, PPARG, SLPI, VIM UP: CDH1, PPARGC1A, PRLR, RAP1GAP, RET,
SLC5A8, TP63,
32 Medullary thyroid cancer 1.50E−03 DOWN: AMY1A (includes others), NTRK2 UP: PRLR, RET
Thyroid gland development 4.71E−03 DOWN: HOXA5, TBX1 UP: RET
168 1.8
131I 24 0.85 Thyroid cancer 1.58E−04 DOWN: AMY1A (includes others), CDKN1A, ECM1, FLT1, MMP2, PPARGC1A, SERPINF1 UP: PPARG, SPP1, TUBA8
8.5 Thyroid cancer 2.05E−03 DOWN: AMY1A (includes others), CDKN1A, MMP2, PPARGC1A, PRLR, SERPINF1 UP: CCND1, PPARG, TUBA8
17 Lack of thyroid gland 9.65E−03 DOWN: FGF10
DOWN and UP indicate down- and upregulation, respectively
Abbreviations: Δt exposure time, D absorbed dose












absorbed dose was tested. Furthermore, hierarchical clus-
tering revealed distinct differences between the transcrip-
tional profiles of both similar and different exposures, e.g.
the transcriptional profiles for 1.4 Gy at 1 and 6 h after
211At administration were distinctly different although the
absorbed dose was similar. This could in part be explained
by the profound differences in dose rate; dose rate effects
on the transcriptional response have previously been
described in vivo following radionuclide administration
[22, 25, 29]. These findings indicate that variations in
the radiation-induced response with absorbed dose will
be reflected in the number of regulated genes, in addition
to which specific genes are regulated, although not in a
clear dose-dependent manner. Instead it is likely that
changes in transcriptional patterns in a specific tissue will
depend with varying degree on, but not excluded to, the
following parameters: exposure time, injected activity,
absorbed dose, dose rate, dose distribution (e.g. frequency
of non-, single- or multi-hit cells) and radiation quality.
Each unique setup of these parameters may then yield a
specific response in the target tissue. In addition, cells are
dynamic systems with complex regulatory networks that
activate cascades of downstream regulation that is sensi-
tive to type and frequency of incoming stimulus.
It is valuable to identify genes with exposure-specific ex-
pression as they may be used as biomarkers. Biomarkers
are useful to better understand the mechanisms behind
the radiation-induced response. A potential application of
biomarkers for ionizing radiation exposure of the thyroid
might be in biological dosimetry after exposure to rela-
tively high doses, maybe in a triage setting. In the present
study, kallikrein 1 (Klk1) and 12 of 13 kallikrein 1-related
(Klk1b) peptidases in the mouse genome were frequently
regulated with fold change values between −3.8 and 110.
The expression of these genes generally increased with
absorbed dose and time after injection of 131I or 211At;
however, 32 Gy resulted in less upregulation compared
with 11 Gy (24 h, 211At) and the highest dose rate used
(1.4 Gy, 1 h, 211At) resulted in downregulation. It is likely
that the expression of Klk1 and Klk1-related peptidases
depends, to a different degree, on dose rate, absorbed dose
and time after injection. In a study on the rat urine prote-
ome 24 h after 10 Gy total body irradiation, the occur-
rence of kallikrein 1-related peptidase b24 precursor
protein increased while the kallikrein-binding serine pro-
tease inhibitor A3K precursor decreased [30]. In another
study, the plasma kallikrein levels decreased with absorbed
dose (0–19 Gy) at 2–24 h after local irradiation of the
hind legs in tumour-bearing rats and controls [31].
Additionally, we have shown that regulation of Klk1 and
Klk1-related genes in mouse thyroids after 131I exposure
does not show a circadian variation [32]. We hypothesize
that genes involved in the kallikrein network may be po-
tential biomarkers of radiation exposure, but further re-
search is warranted to elucidate the relationship between
radiation exposure and kallikrein proteases and kallikrein
inhibitor levels. The kallikrein genes have also been shown
to contribute to the radiation-induced death of various
species. After treatment with soy bean trypsin inhibitors
(SBTI), the mortality rate in mice and chickens 14 days
after exposure to 690 and 820 R (6.7 and 8 Gy to soft tis-
sue), respectively, decreased from 100 to 50 % in mice and
from 86 to 4 % in chickens [33]. The authors suggested
that the decrease in mortality rate after administration of
Table 4 Peroxisomal proliferator-activated receptor (PPAR)-related upstream regulators in thyroids exposed to 131I or 211At according
to IPA upstream regulator analysis
Radionuclide 211At 131I
Time (h) 1 6 24 168 24
Injected activity (kBq) 1.7 100 1.7 7.5 0.064 0.64 1.7 14 42 1.7 13 130 260
Absorbed dose (Gy) 0.023 1.4 0.32 1.4 0.05 0.5 1.4 11 32 1.8 0.85 8.5 17
Gene z score
Pirinixic acid 3.7 4.7 −0.4 −0.4 5.1 3.6 0.8 −1.4 n.s. 3.5 0.9 1.5 0.2
PPARA 2.7 3.9 −0.6 −1.5 5.1 3.7 2.0 −0.9 1.4 2.8 −0.9 −0.1 −0.7
Troglitazone 2.7 5.0 1.6 −0.3 2.9 2.8 1.1 −2.6 −2.2 1.6 −0.1 −1.2 −2.0
Mono-(2-ethylhexyl)phthalate 2.9 5.6 0.6 0.5 5.0 3.1 1.6 n.s. n.s. 2.4 0.9 1.6 0.0
PPARG 2.0 5.2 −0.2 −0.9 4.9 2.3 1.8 −1.1 −0.1 2.6 −0.6 1.3 0.0
PPARGC1A 2.2 4.1 −0.4 1.2 4.5 3.0 0.9 0.8 0.8 2.3 0.0 1.8 0.0
Rosiglitazone 1.0 5.1 −0.7 −2.1 4.6 1.2 1.8 −0.9 −0.2 2.0 1.2 0.7 0.0
PPARD 3.1 3.9 1.5 n.s. 3.5 3.7 n.s. −1.3 n.s. 2.6 −0.8 0.3 n.s.
GW501516 2.6 2.8 0.8 0.8 3.1 3.0 0.0 0.0 0.0 1.8 −1.2 −0.3 0.0
A z score equal to or larger or less than 2 or −2 indicate activated or inhibited upstream regulator, respectively. A z score value between -2 and 2 is considered
not statistically significant. n.s. indicates that IPA was not able to predict upstream regulation of that specific upstream regulator for the specific exposure
condition
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SBTI originated from a radioprotective effect on the vascu-
lar system with less vascular leakage and that the protease
inhibited was likely tissue pre-kallikrein. We suggest that
the radioprotective role of SBTI should be further assessed.
Recurrently regulated genes might be potential bio-
markers and show how different exposure types influ-
ence similar/related genes and biological functions,
although maybe with different magnitude and/or direction
of regulation. The 27 recurrently regulated genes in the
present study were divided into six clusters according to
the transcriptional pattern of each individual gene following
a specific exposure. In cluster 1, 211At-induced regulation
was dependent on both absorbed dose and time after ex-
posure with monotonous change in regulation at 24 h, and
8.5 Gy 131I exposure resulted in very high upregulation.
Genes in cluster 1 are related to muscular activity and/or
calcium activity (Atp2a1, Eno3, Pvalb, Tnnc2, Tnni2 and
Tnnt3). Notably, the thyroid gland contains parafollicular
cells (C-cells) that produce the calcium homeostasis regu-
lating hormone calcitonin. Cluster 2 contains genes related
to various biological functions, e.g. cellular and tissue devel-
opment and wound healing (Ctgf) [34], energy transduction
(Coq10b) and circadian rhythm (Dbp, Per1) [35, 36]. These
genes were generally upregulated and may be indicators of
radiation exposure in general. Cluster 3 consisted of only
one gene (Mfsd2) that was up- and downregulated after
211At and 131I exposure, respectively, indicating a difference
between radiation qualities (Ctgf, Per1, S100a8, S100a9, also
showed a radiation quality dependency). No clear connec-
tion to the immune system, inflammation or the cytokine
system was found for genes in clusters 1–3. However, the
sole gene in cluster 4 (Ltf), all genes in cluster 5 (Ccl8,
Ly6g6d, S100a8, S100a9) and a majority of genes in cluster
6 (Aoc3, Ccl9, Clec2d, Cpa3, Fstl1, Scara3) were related to
the immune system in various ways, and many related to
both inflammation and the cytokine network [37–47]. The
cytokine encoded by Ccl9 is associated with systemic in-
flammation and has increased expression in macrophages
after exposure to triiodothyronine [43]. Lactoferrin—in
mice encoded by the Ltf gene, solely expressed in cluster 4
and generally downregulated—has been patented as a ra-
dioprotective drug and increased survival in mice exposed
to 10 Gy (whole-body, external irradiation) via an impact
on, e.g., cytokine regulation [38]. In cluster 5, genes were
oppositely regulated when comparing 131I and 211At
exposure, indicating a radiation quality-dependent im-
mune response. In cluster 6, genes were downregu-
lated at low absorbed doses and upregulated at high
absorbed dose levels even though the shift from down-
to upregulation occurred at a lower absorbed dose
level for 211At compared with 131I. This suggests that
the radiation-induced regulation of genes in cluster 6
is dependent on both radiation quality and absorbed dose.
The 27 recurrently regulated genes can potentially be used
to discriminate between several different exposure parame-
ters, e.g. radiation quality, absorbed dose levels and time
after administration, and might be considered as potential
biomarkers for at least 131I and 211At exposure of thyroid.
These results indicate a connection between specific expo-
sures and biological responses, especially for the genes in
clusters 4–6 that were clearly associated with immuno-
logical response, inflammation and the cytokine network.
These recurrently regulated genes should be further stud-
ied to better understand their impact on radiation-induced
biological responses and in particular the local and sys-
temic effects that involve inflammation, the immune
system and the cytokine network.
To assess systemic effects from 131I and 211At expos-
ure, regulation of the 27 recurring genes was compared
with transcriptional changes in the lungs, spleen, liver
and kidney cortex and medulla in the same mice dis-
sected in the present study [23, 24]. These non-thyroidal
tissues, that are exposed at a much lower absorbed dose
level compared with thyroid, shared regulation of 19/27
and 6/27 recurring genes after 211At and 131I exposure,
respectively. Additionally, we have previously shown that
the transcriptional response in the lungs, spleen, liver
and kidney cortex and medulla in mice administered 131I
and 211At can partly be explained as a systemic response
from radiation-induced effects on thyroid [32]. One gene
with potential biomarker properties is Dbp. The Dbp gene
expression pattern changed in several non-thyroidal tis-
sues after low absorbed dose level exposure to both 131I
and 211At [23, 24], in kidneys in mice both early and late
after 177Lu-octreotate administration [48], and in rat thy-
roids after 131I administration [49].
A connection to thyroid cancer was detected for 5/27
recurring genes. PVALB has been suggested as an ideal
biomarker to discriminate between benign and malignant
thyroid cancer [50]. ENO3 is another cancer-related gene,
associated to the PAX8-PPARG fusion protein in thyroid
follicular carcinomas, and upstream regulation of PPARs
and PPAR-related pathways was detected in the present
study [51]. The level of CTGF correlated with metastasis,
tumour size and clinical stage for papillary thyroid carcin-
oma in a previous study [52]. Furthermore, undifferenti-
ated thyroid carcinomas have been shown to be S100A8/9
immunopositive and both genes were associated with, e.g.,
inflammation-associated cancer and aggressive breast can-
cer [41, 53, 54].
According to the Ingenuity canonical pathway and dis-
eases and functions analysis tool, the transcriptional re-
sponse after both 131I and 211At exposure was related to
thyroid cancer signalling and various thyroid cancers, re-
spectively. It is uncertain whether induction of thyroid
cancer can be detected at the transcriptional level at these
early times after initiation of radiation exposure. However,
according to IPA, exposure to ionizing radiation activates
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thyroid cancer signalling by rearrangements of RET and/
or NTRK, both present in some of the exposed groups.
Unfortunately, all parts of the thyroid samples from mice
in the three studies this work is based on were used for
microarray analysis, why further studies of genomic rear-
rangements were not possible from the same samples.
Additionally, KLK3 (human denotation of KLK1 in
mouse) is among the involved molecules in all groups
that show an impact on thyroid cancer signalling. Since
IPA uses human protein nomenclature for annotation of
genes, the presence of KLK3 in the IPA analysis is likely
a result of regulation of mouse Klk1 and Klk1-related
genes in the present study.
The number of annotated genes involved in calcium
signalling generally increased with absorbed dose for
211At exposure. Several of the genes associated with
these molecules could be found in cluster 1 among the
27 recurrently regulated genes (Tnni2, Tnnc2, Tnnt3
and Atp2a1). Additionally, gene products of several
other recurrently regulated genes are also calcium-
related according to literature reports, but not associ-
ated with calcium signalling in the IPA canonical path-
way analysis. For example, the gene products of Clec2d
and Ogn both inhibit osteoclasts that can release Ca2+
into the blood [55, 56]. As previously mentioned, the
thyroid gland also contains parafollicular cells that pro-
duce calcitonin, a hormone partly responsible for calcium
homeostasis and an inhibitor of osteoclast activity. How-
ever, the impact on calcitonin levels from 131I and 211At
exposure was not investigated in the present study. A rela-
tionship between calcium and radiation-induced response
has been previously reported and it was shown that cal-
cium was required for bystander-induced apoptosis in un-
irradiated keratinocytes [57].
An impact on integrin-linked kinase (ILK) signalling
was identified using an IPA canonical pathway analysis,
and some genes associated with calcium signalling were
also associated with ILK signalling in the present study.
For 211At, a higher absorbed dose generally resulted in a
response involving a higher number of annotated genes.
For 131I exposure, ILK signalling was only statistically
significant after 8.5 Gy, suggesting a difference in response
due to radiation quality. In blood from mice administered
with 137Cs, genes associated with integrin-signalling were
found upregulated at days 2 and 3 and downregulated at
days 20 and 30 (transcriptional level) [58]. No clear tem-
poral effect on integrin-signalling was seen during the
somewhat shorter time range used in the present study.
Interestingly, however, in the present study, we demon-
strate that genes, e.g., associated with ILK signalling were
generally upregulated at higher absorbed dose levels and
downregulated at lower absorbed dose levels, suggesting
different involvement of this signalling pathway at differ-
ent absorbed dose levels. This was especially the case 24 h
after 211At administration, but a similar trend was also
seen after 131I administration. ILK signalling and radiation
damage have been previously connected, and furthermore,
ILK signalling partly controls cell adhesion and mediates
prosurvival and antiapoptotic signalling after exposure to
ionizing radiation [59]. Additionally, several cell adhesion
GO terms were identified when performing in-depth sep-
arate analysis of the transcriptional response of thyroid tis-
sue from animals in the three experiments that constitute
the present study [20–22].
In the present study, the predicted upstream regula-
tion of several peroxisomal proliferator-activated re-
ceptors (PPARs), and PPAR ligands and agonists was
found. The PPARs are of interest in the radiation-
induced biological response. In one study, administra-
tion of the PPARα agonist fenofibrate prevented some
cognitive function impairment in young rats exposed
to 40 Gy fractionated whole-brain irradiation [60]. In
another study, knockout of PPARα resulted in inhibition of
radiation-induced apoptosis in the mouse kidney through
regulation of Nfkb and anti-apoptosis factors [61]. Together,
these results indicate that the PPAR network may play a
role in radiation-induced biological response and that it
may be targeted to modulate radiation damage in vari-
ous tissues.
Conclusions
A profound effect on gene expression in mouse thyroid
tissue after 131I and 211At exposure was detected, and 27
genes, of which many are associated with immune re-
sponse, were identified as potential biomarkers for 131I
and 211At exposure, and the biomarker applicability of
these genes should be further studied. Hierarchical clus-
tering revealed distinct differences between transcrip-
tional profiles of both similar and different exposures,
demonstrating the necessity for better understanding of
radiation-induced changes in cellular activity. Addition-
ally, the kallikrein network deserves further attention
since literature shows how administration of protease in-
hibitors, known to decrease kallikrein levels, drastically
increased survival in various irradiated species. An effect
on thyroid cancer signalling was identified, as well as
regulation of several genes previously identified as bio-
markers for thyroid cancer; however, it is unlikely that
thyroid cancer can be manifested at the transcriptional
level at these early times after initiation of radiation ex-
posure. Furthermore, the present study supports that
ionizing radiation may impact calcium-related biological
processes. Taken together, we consider RNA microar-
rays, especially in the in vivo setting, to be an important
tool to gain further insight in the complex radiation-
induced changes in cellular activity and affected path-
ways, and for biomarker discovery.
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